Objectives: This study aimed to evaluate the effectiveness of a multidisciplinary pulmonary rehabilitation program at Ewha Womans University Mokdong Hospital, Korea that was designed to augment respiratory function, promote patient recovery, and improve discharge outcomes.

Methods: This study was conducted as part of quality improvement activities from March to August 2023. A multidisciplinary pulmonary rehabilitation team was established, comprising specialists in rehabilitation medicine, pulmonology, and thoracic surgery, as well as physical and occupational therapists, and the nutrition team. We developed a comprehensive rehabilitation program that included stretching, strengthening exercises, aerobic training, and respiratory retraining, supplemented by individualized treatments such as bedside and ambulatory physical therapy. Evaluations before and after rehabilitation were performed using the Modified Medical Research Council Dyspnea Scale and the Chronic Obstructive Pulmonary Disease Assessment Test. The primary indicators of success were an increase of over 10% in pulmonary rehabilitation consultations and an improvement in discharge-to-home rates.

Results: The total number of pulmonary rehabilitation cases rose by 79.16%, from 24 to 43, while consultations saw a 21.15% increase, from 52 to 63. Of the 63 pulmonary rehabilitation cases, 32 (50.8%) were transferred to other hospitals, 25 (39.7%) were discharged home, and 6 (9.5%) remained hospitalized.

Conclusion: The study demonstrated the effectiveness of a multidisciplinary pulmonary rehabilitation approach in improving program participation and achieving meaningful discharge outcomes. These findings underscore the potential for expanding multidisciplinary efforts and highlight the need for further studies to increase discharge-to-home rates and evaluate the long-term impacts of such programs.

Purpose: Thrombosis and bleeding significantly affect morbidity and mortality in myeloproliferative neoplasms (MPNs). The efficacy and safety of direct oral anticoagulants (DOACs) in MPN patients remain uncertain. Materials and Methods: We conducted a large, retrospective, nationwide cohort study using the Korean Health Insurance Review and Assessment Service database from 2010 to 2021. Results: Out of the 368 MPN patients included in the final analysis, 62.8% were treated with DOACs for atrial fibrillation (AF), and 37.2% for venous thromboembolism (VTE). The AF group was statistically older with higher CHA2DS2-VASc (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke, transient ischemic attack, or thromboembolism, vascular disease, age 65-74 years, sex category [female]) scores compared to the VTE group. Antiplatelet agents were used in 51.1% of cases, and cytoreductive drugs in 79.3%, with hydroxyurea being the most common (64.9%). The median follow-up was 22.3 months, with 1-year cumulative incidence rates of thrombosis and bleeding at 11.1% and 3.7%, respectively. Multivariate analysis identified CHA2DS2-VASc scores ≥ 3 (hazard ratio [HR], 3.48), concomitant antiplatelet use (HR, 2.57), and cytoreduction (HR, 2.20) as significant thrombosis risk factors but found no significant predictors for major bleeding. Conclusion Despite the limitations of retrospective data, DOAC treatment in MPN patients seems effective and has an acceptable bleeding risk.

Purpose: Some studies suggest that TP53 mutations are associated with the response to immune checkpoint inhibitors (ICI) in patients with non–small cell lung cancer (NSCLC) and also contribute to sex disparities in several cancers. Thus, we hypothesized that TP53 mutations might serve as sex-dependent genomic biomarkers of ICI treatment response in patients with NSCLC. Materials and Methods: Clinical data of 100 patients with metastatic NSCLC treated with ICI monotherapy at Seoul National University Bundang Hospital (SNUBH) were retrospectively reviewed. Genomic and clinical datasets of The Cancer Genome Atlas and an ICI-treated lung cancer cohort (cBioPortal) were also analyzed. Results: In SNUBH cohort, no statistically significant difference was observed in the median progression-free survival (PFS) according to TP53 mutation status (p=0.930); however, female patients with TP53 mutations (MT) had a significantly prolonged median PFS compared to wild-type (WT) (6.1 months in TP53 MT vs. 2.6 months in TP53 WT; p=0.021). Programmed death-ligand 1 (PD-L1) high (≥ 50%) expression was significantly enriched in female patients with TP53 MT (p=0.005). The analysis from publicly available dataset also revealed that females with NSCLC with TP53 MT showed significantly longer PFS than those with TP53 WT (p < 0.001). In The Cancer Genome Atlas analysis, expression of immune-related genes, and tumor mutation burden score in TP53 MT females were higher than in males without TP53 MT. Conclusion Female patients with NSCLC with TP53 mutations had high PD-L1 expression and showed favorable clinical outcomes following ICI therapy, suggesting a need for further research to explore the role of TP53 mutations for sex disparities in response to ICI therapy.

Purpose: Thrombosis and bleeding significantly affect morbidity and mortality in myeloproliferative neoplasms (MPNs). The efficacy and safety of direct oral anticoagulants (DOACs) in MPN patients remain uncertain. Materials and Methods: We conducted a large, retrospective, nationwide cohort study using the Korean Health Insurance Review and Assessment Service database from 2010 to 2021. Results: Out of the 368 MPN patients included in the final analysis, 62.8% were treated with DOACs for atrial fibrillation (AF), and 37.2% for venous thromboembolism (VTE). The AF group was statistically older with higher CHA2DS2-VASc (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke, transient ischemic attack, or thromboembolism, vascular disease, age 65-74 years, sex category [female]) scores compared to the VTE group. Antiplatelet agents were used in 51.1% of cases, and cytoreductive drugs in 79.3%, with hydroxyurea being the most common (64.9%). The median follow-up was 22.3 months, with 1-year cumulative incidence rates of thrombosis and bleeding at 11.1% and 3.7%, respectively. Multivariate analysis identified CHA2DS2-VASc scores ≥ 3 (hazard ratio [HR], 3.48), concomitant antiplatelet use (HR, 2.57), and cytoreduction (HR, 2.20) as significant thrombosis risk factors but found no significant predictors for major bleeding. Conclusion Despite the limitations of retrospective data, DOAC treatment in MPN patients seems effective and has an acceptable bleeding risk.

Purpose: Some studies suggest that TP53 mutations are associated with the response to immune checkpoint inhibitors (ICI) in patients with non–small cell lung cancer (NSCLC) and also contribute to sex disparities in several cancers. Thus, we hypothesized that TP53 mutations might serve as sex-dependent genomic biomarkers of ICI treatment response in patients with NSCLC. Materials and Methods: Clinical data of 100 patients with metastatic NSCLC treated with ICI monotherapy at Seoul National University Bundang Hospital (SNUBH) were retrospectively reviewed. Genomic and clinical datasets of The Cancer Genome Atlas and an ICI-treated lung cancer cohort (cBioPortal) were also analyzed. Results: In SNUBH cohort, no statistically significant difference was observed in the median progression-free survival (PFS) according to TP53 mutation status (p=0.930); however, female patients with TP53 mutations (MT) had a significantly prolonged median PFS compared to wild-type (WT) (6.1 months in TP53 MT vs. 2.6 months in TP53 WT; p=0.021). Programmed death-ligand 1 (PD-L1) high (≥ 50%) expression was significantly enriched in female patients with TP53 MT (p=0.005). The analysis from publicly available dataset also revealed that females with NSCLC with TP53 MT showed significantly longer PFS than those with TP53 WT (p < 0.001). In The Cancer Genome Atlas analysis, expression of immune-related genes, and tumor mutation burden score in TP53 MT females were higher than in males without TP53 MT. Conclusion Female patients with NSCLC with TP53 mutations had high PD-L1 expression and showed favorable clinical outcomes following ICI therapy, suggesting a need for further research to explore the role of TP53 mutations for sex disparities in response to ICI therapy.

Objectives: This study aimed to evaluate the effectiveness of a multidisciplinary pulmonary rehabilitation program at Ewha Womans University Mokdong Hospital, Korea that was designed to augment respiratory function, promote patient recovery, and improve discharge outcomes.

Methods: This study was conducted as part of quality improvement activities from March to August 2023. A multidisciplinary pulmonary rehabilitation team was established, comprising specialists in rehabilitation medicine, pulmonology, and thoracic surgery, as well as physical and occupational therapists, and the nutrition team. We developed a comprehensive rehabilitation program that included stretching, strengthening exercises, aerobic training, and respiratory retraining, supplemented by individualized treatments such as bedside and ambulatory physical therapy. Evaluations before and after rehabilitation were performed using the Modified Medical Research Council Dyspnea Scale and the Chronic Obstructive Pulmonary Disease Assessment Test. The primary indicators of success were an increase of over 10% in pulmonary rehabilitation consultations and an improvement in discharge-to-home rates.

Results: The total number of pulmonary rehabilitation cases rose by 79.16%, from 24 to 43, while consultations saw a 21.15% increase, from 52 to 63. Of the 63 pulmonary rehabilitation cases, 32 (50.8%) were transferred to other hospitals, 25 (39.7%) were discharged home, and 6 (9.5%) remained hospitalized.

Conclusion: The study demonstrated the effectiveness of a multidisciplinary pulmonary rehabilitation approach in improving program participation and achieving meaningful discharge outcomes. These findings underscore the potential for expanding multidisciplinary efforts and highlight the need for further studies to increase discharge-to-home rates and evaluate the long-term impacts of such programs.

Objectives: This study aimed to evaluate the effectiveness of a multidisciplinary pulmonary rehabilitation program at Ewha Womans University Mokdong Hospital, Korea that was designed to augment respiratory function, promote patient recovery, and improve discharge outcomes.

Methods: This study was conducted as part of quality improvement activities from March to August 2023. A multidisciplinary pulmonary rehabilitation team was established, comprising specialists in rehabilitation medicine, pulmonology, and thoracic surgery, as well as physical and occupational therapists, and the nutrition team. We developed a comprehensive rehabilitation program that included stretching, strengthening exercises, aerobic training, and respiratory retraining, supplemented by individualized treatments such as bedside and ambulatory physical therapy. Evaluations before and after rehabilitation were performed using the Modified Medical Research Council Dyspnea Scale and the Chronic Obstructive Pulmonary Disease Assessment Test. The primary indicators of success were an increase of over 10% in pulmonary rehabilitation consultations and an improvement in discharge-to-home rates.

Results: The total number of pulmonary rehabilitation cases rose by 79.16%, from 24 to 43, while consultations saw a 21.15% increase, from 52 to 63. Of the 63 pulmonary rehabilitation cases, 32 (50.8%) were transferred to other hospitals, 25 (39.7%) were discharged home, and 6 (9.5%) remained hospitalized.

Conclusion: The study demonstrated the effectiveness of a multidisciplinary pulmonary rehabilitation approach in improving program participation and achieving meaningful discharge outcomes. These findings underscore the potential for expanding multidisciplinary efforts and highlight the need for further studies to increase discharge-to-home rates and evaluate the long-term impacts of such programs.

Objectives: This study aimed to evaluate the effectiveness of a multidisciplinary pulmonary rehabilitation program at Ewha Womans University Mokdong Hospital, Korea that was designed to augment respiratory function, promote patient recovery, and improve discharge outcomes.

Methods: This study was conducted as part of quality improvement activities from March to August 2023. A multidisciplinary pulmonary rehabilitation team was established, comprising specialists in rehabilitation medicine, pulmonology, and thoracic surgery, as well as physical and occupational therapists, and the nutrition team. We developed a comprehensive rehabilitation program that included stretching, strengthening exercises, aerobic training, and respiratory retraining, supplemented by individualized treatments such as bedside and ambulatory physical therapy. Evaluations before and after rehabilitation were performed using the Modified Medical Research Council Dyspnea Scale and the Chronic Obstructive Pulmonary Disease Assessment Test. The primary indicators of success were an increase of over 10% in pulmonary rehabilitation consultations and an improvement in discharge-to-home rates.

Results: The total number of pulmonary rehabilitation cases rose by 79.16%, from 24 to 43, while consultations saw a 21.15% increase, from 52 to 63. Of the 63 pulmonary rehabilitation cases, 32 (50.8%) were transferred to other hospitals, 25 (39.7%) were discharged home, and 6 (9.5%) remained hospitalized.

Conclusion: The study demonstrated the effectiveness of a multidisciplinary pulmonary rehabilitation approach in improving program participation and achieving meaningful discharge outcomes. These findings underscore the potential for expanding multidisciplinary efforts and highlight the need for further studies to increase discharge-to-home rates and evaluate the long-term impacts of such programs.

Purpose: Thrombosis and bleeding significantly affect morbidity and mortality in myeloproliferative neoplasms (MPNs). The efficacy and safety of direct oral anticoagulants (DOACs) in MPN patients remain uncertain. Materials and Methods: We conducted a large, retrospective, nationwide cohort study using the Korean Health Insurance Review and Assessment Service database from 2010 to 2021. Results: Out of the 368 MPN patients included in the final analysis, 62.8% were treated with DOACs for atrial fibrillation (AF), and 37.2% for venous thromboembolism (VTE). The AF group was statistically older with higher CHA2DS2-VASc (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke, transient ischemic attack, or thromboembolism, vascular disease, age 65-74 years, sex category [female]) scores compared to the VTE group. Antiplatelet agents were used in 51.1% of cases, and cytoreductive drugs in 79.3%, with hydroxyurea being the most common (64.9%). The median follow-up was 22.3 months, with 1-year cumulative incidence rates of thrombosis and bleeding at 11.1% and 3.7%, respectively. Multivariate analysis identified CHA2DS2-VASc scores ≥ 3 (hazard ratio [HR], 3.48), concomitant antiplatelet use (HR, 2.57), and cytoreduction (HR, 2.20) as significant thrombosis risk factors but found no significant predictors for major bleeding. Conclusion Despite the limitations of retrospective data, DOAC treatment in MPN patients seems effective and has an acceptable bleeding risk.

Purpose: Some studies suggest that TP53 mutations are associated with the response to immune checkpoint inhibitors (ICI) in patients with non–small cell lung cancer (NSCLC) and also contribute to sex disparities in several cancers. Thus, we hypothesized that TP53 mutations might serve as sex-dependent genomic biomarkers of ICI treatment response in patients with NSCLC. Materials and Methods: Clinical data of 100 patients with metastatic NSCLC treated with ICI monotherapy at Seoul National University Bundang Hospital (SNUBH) were retrospectively reviewed. Genomic and clinical datasets of The Cancer Genome Atlas and an ICI-treated lung cancer cohort (cBioPortal) were also analyzed. Results: In SNUBH cohort, no statistically significant difference was observed in the median progression-free survival (PFS) according to TP53 mutation status (p=0.930); however, female patients with TP53 mutations (MT) had a significantly prolonged median PFS compared to wild-type (WT) (6.1 months in TP53 MT vs. 2.6 months in TP53 WT; p=0.021). Programmed death-ligand 1 (PD-L1) high (≥ 50%) expression was significantly enriched in female patients with TP53 MT (p=0.005). The analysis from publicly available dataset also revealed that females with NSCLC with TP53 MT showed significantly longer PFS than those with TP53 WT (p < 0.001). In The Cancer Genome Atlas analysis, expression of immune-related genes, and tumor mutation burden score in TP53 MT females were higher than in males without TP53 MT. Conclusion Female patients with NSCLC with TP53 mutations had high PD-L1 expression and showed favorable clinical outcomes following ICI therapy, suggesting a need for further research to explore the role of TP53 mutations for sex disparities in response to ICI therapy.